PT0511 / PAQ Therapeutics - LARVOL DELTA

PAQ Therapeutics…announced the closing of a Series B extension, bringing the company's total Series B financing to $77 million, and the dosing of the first patient in a Phase 1 clinical trial evaluating PT0511, the company's pan-KRAS degrader (PRNewswire) - "The Series B extension builds on PAQ's previously announced Series B financing, with participation from existing as well as new investors, and further strengthens the company's balance sheet to advance multiple clinical programs. Proceeds from the financing will support the ongoing Phase 1 development of PT0253, PAQ's KRAS G12D degrader, as well as the clinical advancement of PT0511....The Phase 1 study is a first-in-human, open-label, dose-escalation trial evaluating the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of PT0511 in patients with advanced solid tumors harboring KRAS alterations."

Financing • Trial status • Colorectal Cancer • Non Small Cell Lung Cancer • Pancreatic Cancer